Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Lundbeck Boosts US R&D Capability With $400m Abide Theraputics Bid

May 06 2019

• By Mike Ward

nerve cells, concept for neurodegenerative and neurological disease — Lundbeck seeks new pathways to brain diseases • Source: Shutterstock

Related Content

Cannabinoid Market Snapshot: GW's Epilepsy Success Bodes Well

Nov 25 2016

Lundbeck Looks For Assets Across Value Chain To Ride Storm

Feb 08 2019

Pressure Builds On Lundbeck After Rexulti Fails In Bipolar I Manic Episodes

Feb 15 2019

Valbenazine's Consistent But Weak Effect In Tourette Dismays Neurocrine

Dec 13 2018

Lundbeck Still Assessing Future Of Antipsychotic After Phase III Failure, Says CEO

Nov 19 2018

Related Companies

H. Lundbeck A/S

Abide Therapeutics Inc.

The Scripps Research Institute (TSRI)

Vividion Therapeutics, Inc.

Kyorin Pharmaceutical Co., Ltd.

Bristol Myers Squibb Company

Additional Topics

M & A Platform Technologies Deals Commercial Neurology BioPharmaceutical

More from Deals

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window